Evaluation of efficacy of PDE5 inhibiter by penile blood pressure for benign prostatic hyperplasia patients with lower urinary tract symptoms: MP09‐07
Abstract
You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2017MP09-07 EVALUATION OF EFFICACY OF PDE5 INHIBITER BY PENILE BLOOD PRESSURE FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS WITH LOWER URINARY TRACT SYMPTOMS Juntaro Koyama, Yoshihide Kawasaki, Tomonori Sato, Taro Fukushi, Atsushi Kyan, and Yasuhiro Kaiho Juntaro KoyamaJuntaro Koyama More articles by this author , Yoshihide KawasakiYoshihide Kawasaki More articles by this author , Tomonori SatoTomonori Sato More articles by this author , Taro FukushiTaro Fukushi More articles by this author , Atsushi KyanAtsushi Kyan More articles by this author , and Yasuhiro KaihoYasuhiro Kaiho More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.315AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Tadalafil is a phosphodiesterase 5 inhibitor that affects cyclic guanosine monophosphate (cGMP). It is known to improve not only smooth muscle relaxation of the prostatic urethra and bladder, but also pelvic ischemia. In the daily clinic, tadalafil is usually prescribed for patients with lower urinary tract symptoms (LUTS), but not all patients respond to tadalafil treatment. The purpose of this study was to identify those who would be good candidates for tadalafil. This evaluation used penile blood pressure (PBP) as a feasible and reproducible method related to…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.